BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 21321270)

  • 1. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.
    Tixier F; Le Rest CC; Hatt M; Albarghach N; Pradier O; Metges JP; Corcos L; Visvikis D
    J Nucl Med; 2011 Mar; 52(3):369-78. PubMed ID: 21321270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
    Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
    J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET.
    Tixier F; Hatt M; Le Rest CC; Le Pogam A; Corcos L; Visvikis D
    J Nucl Med; 2012 May; 53(5):693-700. PubMed ID: 22454484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumor Textural Heterogeneity on Pretreatment (18)F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer.
    Oh JS; Kang BC; Roh JL; Kim JS; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Aug; 22(8):2746-54. PubMed ID: 25487968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline ¹⁸F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer.
    Hatt M; Visvikis D; Pradier O; Cheze-le Rest C
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1595-606. PubMed ID: 21559979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
    Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Texture analysis of
    Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
    BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
    Dimitrakopoulou-Strauss A; Strauss L
    Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    Goodman KA; Ou FS; Hall NC; Bekaii-Saab T; Fruth B; Twohy E; Meyers MO; Boffa DJ; Mitchell K; Frankel WL; Niedzwiecki D; Noonan A; Janjigian YY; Thurmes PJ; Venook AP; Meyerhardt JA; O'Reilly EM; Ilson DH
    J Clin Oncol; 2021 Sep; 39(25):2803-2815. PubMed ID: 34077237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.
    Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P; Buvat I
    J Nucl Med; 2011 Mar; 52(3):354-61. PubMed ID: 21345787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
    Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
    J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional positron emission tomography image texture analysis of esophageal squamous cell carcinoma: relationship between tumor 18F-fluorodeoxyglucose uptake heterogeneity, maximum standardized uptake value, and tumor stage.
    Dong X; Xing L; Wu P; Fu Z; Wan H; Li D; Yin Y; Sun X; Yu J
    Nucl Med Commun; 2013 Jan; 34(1):40-6. PubMed ID: 23111378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.
    Hatt M; Le Pogam A; Visvikis D; Pradier O; Cheze Le Rest C
    J Nucl Med; 2012 Jan; 53(1):12-20. PubMed ID: 22213819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
    Tandberg DJ; Cui Y; Rushing CN; Hong JC; Ackerson BG; Marin D; Zhang X; Czito BG; Willett CW; Palta M
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1002-1007. PubMed ID: 30055238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.